Curium Pharma, a provider of nuclear medicine services, announces the successful completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a prominent player in nuclear medicine based in Istanbul, Turkey.
This strategic acquisition significantly boosts Curium’s Lutetium-177 (Lu-177) manufacturing capabilities to address rising global demand for the isotope. It also secures supply for the future launch of Curium’s Lu-177 drug candidates targeting prostate cancer (currently in development) and neuroendocrine tumors (pending approval). Moreover, Monrol’s innovative research and development expertise will complement Curium’s efforts to expand its portfolio of theranostic products. Curium plans to globally deploy Monrol’s Ga-68 generator, subject to regulatory approvals.
The acquisition also broadens Curium’s PET and SPECT geographical footprint. With the addition of 12 Monrol-owned and partnered sites in Eastern Europe and MENA regions, Curium’s PET network expands from 34 locations in Western Europe and Asia to 46 globally. Furthermore, Monrol’s manufacturing and logistics infrastructure in Istanbul enhances Curium’s vertically integrated production and distribution capabilities.
Curium remains committed to navigating regulatory approvals efficiently as part of this transaction. The acquisition marks a significant milestone in advancing nuclear medicine solutions globally.